PMID- 31354244
OWN - NLM
STAT- MEDLINE
DCOM- 20200206
LR  - 20200225
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 13
DP  - 2019
TI  - Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque 
      psoriasis.
PG  - 1993-2000
LID - 10.2147/DDDT.S137588 [doi]
AB  - The approval of guselkumab marks the entry of the IL-23 inhibitor class into the 
      therapeutic armamentarium for patients with moderate-to-severe plaque psoriasis. 
      This class specifically targets the upstream portion of the type 17 helper T 
      (Th17) axis, which has been implicated as a key driver of the abnormal 
      inflammatory state observed in psoriasis. Guselkumab is highly efficacious, with 
      over 85% of the patients achieving >/=75% reduction in Psoriasis Area and Severity 
      Index from baseline (PASI 75) and over 70% of the patients achieving PASI 90 
      response in its Phase III clinical trials. Additionally, this medication is 
      well-tolerated, with non-serious infections such as nasopharyngitis and upper 
      respiratory infections (URIs) being the most common adverse events (AEs) reported 
      in its clinical trials. Guselkumab offers yet another effective treatment option 
      in the rapidly growing list of available biological therapies for 
      moderate-to-severe plaque psoriasis.
FAU - Yang, Eric J
AU  - Yang EJ
AD  - Department of Dermatology, University of California San Francisco, San Francisco, 
      CA, USA; ericjyang@outlook.com.
AD  - Chicago Medical School, Rosalind Franklin University of Medicine and Science, 
      North Chicago, IL, USA; ericjyang@outlook.com.
FAU - Smith, Mary Patricia
AU  - Smith MP
AD  - Department of Dermatology, University of California San Francisco, San Francisco, 
      CA, USA; ericjyang@outlook.com.
AD  - Icahn School of Medicine at Mount Sinai, New York, NY, USA.
FAU - Ly, Karen
AU  - Ly K
AD  - Department of Dermatology, University of California San Francisco, San Francisco, 
      CA, USA; ericjyang@outlook.com.
AD  - School of Medicine, Wayne State University, Detroit, MI, USA.
FAU - Bhutani, Tina
AU  - Bhutani T
AD  - Department of Dermatology, University of California San Francisco, San Francisco, 
      CA, USA; ericjyang@outlook.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190618
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Interleukin-23)
RN  - 089658A12D (guselkumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/*pharmacology/*therapeutic use
MH  - Clinical Trials, Phase III as Topic
MH  - Humans
MH  - Interleukin-23/*antagonists & inhibitors
MH  - Psoriasis/*drug therapy/physiopathology
PMC - PMC6587972
OTO - NOTNLM
OT  - IL-23 inhibitor
OT  - biologic selection
OT  - biologics
OT  - guselkumab
OT  - plaque psoriasis
COIS- Disclosure T Bhutani is an investigator for AbbVie, Janssen, Merck, Eli Lilly, 
      and Strata Skin Sciences and an advisor for Regeneron. The other authors report 
      no conflicts of interest in this work.
EDAT- 2019/07/30 06:00
MHDA- 2020/02/07 06:00
PMCR- 2019/06/18
CRDT- 2019/07/30 06:00
PHST- 2019/07/30 06:00 [entrez]
PHST- 2019/07/30 06:00 [pubmed]
PHST- 2020/02/07 06:00 [medline]
PHST- 2019/06/18 00:00 [pmc-release]
AID - dddt-13-1993 [pii]
AID - 10.2147/DDDT.S137588 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2019 Jun 18;13:1993-2000. doi: 10.2147/DDDT.S137588. 
      eCollection 2019.